IAMA Therapeutics

Iama therapeutics email format

Verified email-pattern data for Iama Therapeutics is currently limited. You can still use the company insights and contact sections below.
IAMA Therapeutics is a clinical-stage pharmaceutical company raising a Series B to fund the clinical development of its lead candidate in epilepsy and neurodevelopment disorders. The Company’s lead candidate, IAMA-6, is a "best-in-class" selective NKCC1 inhibitor being developed for various orphan brain disorders, including drug-resistant epilepsy, and started the Phase 1 clinical trial in January 2024. Other pipeline candidates include new molecular entities to target Cation Chloride Cotransporters in pediatric neuropsychiatric conditions.
Looking for a particular IAMA Therapeutics employee's phone or email?

Iama Therapeutics Questions

Top IAMA Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant